Richard S. Eiswirth, Jr. Sells 13,410 Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) Stock

Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 13,410 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $1.20, for a total value of $16,092.00. Following the transaction, the insider now owns 84,779 shares of the company’s stock, valued at $101,734.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) remained flat at $$1.09 during midday trading on Friday. 256,305 shares of the company were exchanged, compared to its average volume of 161,069. Alimera Sciences, Inc. has a 12 month low of $1.03 and a 12 month high of $1.72. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71.

A hedge fund recently raised its stake in Alimera Sciences stock. Stonepine Capital Management LLC grew its holdings in Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 477,226 shares of the biopharmaceutical company’s stock after buying an additional 292,399 shares during the period. Alimera Sciences accounts for about 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned approximately 0.69% of Alimera Sciences worth $644,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.77% of the company’s stock.

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Alimera Sciences in a report on Monday, January 22nd. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. ValuEngine cut Alimera Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 3rd. Finally, Cowen reissued a “buy” rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Alimera Sciences currently has a consensus rating of “Hold” and a consensus price target of $3.38.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Insider Buying and Selling by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply